DEFLECT III: A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During TAVI

Keystone Heart

Status

Completed

Conditions

Aortic Valve Stenosis

Treatments

Device: TriGuard HDH

Study type

Interventional

Funder types

Industry

Identifiers

NCT02070731

DEFLECT III

Details and patient eligibility

About

A randomized evaluation of the TriGuard™ HDH embolic deflection device during transcatheter aortic valve implantation.

Full description

The TriGuard HDH device is an aortic embolism deflection device intended to reduce the amount of embolic material that may enter the carotid, subclavian, and vertebral arteries during transcatheter heart valve implantation.

To assess the safety, efficacy, and performance of the TriGuard HDH embolic deflection device in patients undergoing transcatheter aortic valve implantation (TAVI), in comparison with patients undergoing unprotected TAVI.

Subjects with indications for TAVI and who meet study eligibility criteria will be randomized 1:1 to one of two treatment arms:

Intervention - TAVI with the TriGuard HDH embolic deflection device
Control - standard unprotected TAVI

Enrollment

86 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The patient is a male or non-pregnant female ≥18 years of age
Patient meets indications for TAVI
The patient is willing to comply with protocol-specified follow-up evaluations
The patient, or legally authorized representative, has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB)

Exclusion criteria

Patients undergoing TAVI via the trans-axillary, trans-subclavian, or trans-aortic route
Patients undergoing TAVI via the transapical approach due to friable or mobile atherosclerotic plaque in the aortic arch
Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to index procedure per site standard test
Patients with known diagnosis of acute myocardial infarction (AMI) within 72 hours preceding the index procedure (according to definition) or AMI >72 hours preceding the index procedure, in whom creatine kinase and creatine kinase-Muscle Brain have not returned to within normal limits at the time of procedure.
Patients who are currently experiencing clinical symptoms consistent with new-onset AMI, such as nitrate-unresponsive prolonged chest pain
Patients with a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated, or who will refuse transfusion
Patients with known other mental or physical illness or known history of substance abuse that may cause non-compliance with the protocol, confound the data interpretation, or is associated with a life expectancy of less than one year
Patients with severe allergy to heparin or known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel, nitinol, stainless steel alloy, and/or contrast sensitivity that cannot be adequately pre-medicated
Patients with a history of a stroke or transient ischemic attack (TIA) within the prior 6 months
Patients with an active peptic ulcer or history of upper gastrointestinal (GI) bleeding within the prior 6 months
Patients with renal failure (estimated Glomerular Filtration Rate [estimated Glomerular Filtration Rate] <30 mL/min, calculated from serum creatinine by the Cockcroft-Gault formula)
Patients with hepatic failure (Child-Pugh class C)
Patients with hypercoagulable states that cannot be corrected by additional periprocedural heparin
Patients presenting with cardiogenic shock or severe hypotension (systolic blood pressure <90 mm Hg) at the time of the index procedure
Patients with severe peripheral arterial disease that precludes delivery sheath vascular access
Patients with a heavily calcified or severely atheromatous aortic arch
Patients with an innominate artery ostium diameter <11 mm
Patients with a transverse aortic diameter >40 mm
Patients with anatomic irregularities of the aortic arch or innominate artery that could prevent positioning and stability of the device
Patients with contraindication to cerebral MRI
Patients who have a planned treatment with any other investigational device or procedure during the study period
Patients planned to undergo any other cardiac surgical or interventional procedure (e.g., concurrent coronary revascularization) during the TAVI procedure or within two (2) weeks prior to the TAVI procedure.